Some have warned that, once semaglutide is no longer in shortage (which may be in a matter of days), the compounded semaglutide market would no longer be legally viable and would face an onslaught of lawsuits from Novo Nordisk, semaglutides manufacturer
Semaglutyd na odchudzanie
10.1126/science.1224631 101
Brait, M., Ling, S., Nagpal, J
The focus of this mini-review is to present a brief overview of the synthetic short peptide tirzepatide as the first dual GLP-1 and GIP receptor agonist as a promising therapeutic agent for the treatment of either diabetes or obesity and to highlight its superiority to other similar agents
Above is the packaging- black & rubberized